Polycystic Ovary Syndrome
Pipeline by Development Stage
Drug Modality Breakdown
Women's Health is a $989M market with mature, consolidated portfolios dominated by legacy hormone therapies and specialty oncology agents.
Key Trends
- Heavy concentration in estrogen receptor agonists and single-blockbuster dependency (INLYTA 47% of market)
- Multiple patent cliffs 2027-2030 creating near-term revenue pressure and consolidation risk
- Hiring concentrated in commercial and specialty recruitment, not R&D expansion
Career Verdict
Viable but cautious entry point—stable commercial roles available, but limited innovation pipeline and impending LOE events suggest a mature market in defensive posture rather than growth mode.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | INLYTA (axitinib) | Pfizer | $0.467B | 47% | Peak | Stable | 11.2yr |
| 2 | KORLYM (mifepristone) | Corcept Therapeutics | $0.229B | 23% | Peak | Stable | 12.2yr |
| 3 | LUPRON DEPOT (leuprolide acetate) | AbbVie | $0.129B | 13% | LOE Approaching | Declining | |
| 4 | ESTRING (estradiol) | Pfizer | $0.050B | 5% | LOE Approaching | Declining | |
| 5 | PREMPRO (conjugated estrogens/medroxyprogesterone) | Pfizer | $0.040B | 4% | LOE Approaching | Declining |
Drug Class Breakdown
single-product dominance (INLYTA)
concentrated in specialty reproductive health
legacy product with pending LOE pressure
fragmented across 17 products, majority LOE-approaching
minor indication-specific use
niche positioning, small market share
Career Outlook
StableWomen's Health is a mature, consolidated market where career growth is incremental rather than exponential. Pfizer and AbbVie control ~61% of spending via blockbuster and legacy products, creating stable but competitive commercial environments. Impending patent cliffs (2027-2030) and fragmented early-stage pipeline suggest cost containment and defensive strategy dominance over expansion, meaning fewer senior advancement slots and limited innovation-driven upside. Opportunity exists in specialty segments (fertility platforms, digital health, device innovation) outside traditional pharma.
Breaking In
Target specialty commercial roles (MSL, outcomes research) or non-traditional employers (Progyny, digital health startups, device firms) rather than incumbent pharma, which offers less differentiation for new entrants.
For Experienced Professionals
Experienced professionals should assess portfolio defensibility and patent cliff timing before joining a company; AbbVie and Pfizer offer scale but entail consolidation risk, while boutique firms (Corcept, Duchesnay) offer strategic leverage in niche areas.
In-Demand Skills
Best For
Hiring Landscape
Women's Health hiring totals 117 jobs, but data shows significant reporting gaps (many major companies report 0 jobs despite large portfolios). Visible hiring is concentrated in Viatris (40 jobs, likely manufacturing/supply chain post-spinoff), Progyny (29 jobs, fertility/reproductive benefits platform), and specialized device/diagnostics firms (GE HealthCare, Caldera Medical, Natera). Commercial roles dominate disclosed positions (65 of 109 departmental roles), with IT second (7 roles at $222K avg, reflecting digital health emphasis).
Top Hiring Companies
By Department
Commercial and specialty sales roles offer stable near-term opportunity, but modest average salary ($82K commercial) and portfolio maturity suggest limited high-growth compensation upside; IT roles offer premium but are scarce.
Competitive Landscape
18 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 43 trials with date data
Clinical Trials (43)
Total enrollment: 7,212 patients across 43 trials
Clinical、metabolomics and the Study of Intestinal Flora of Jinfeng Pills in the Treatment of Polycystic Ovary Syndrome
Metformin vs Metformin Combined With GLP-1RA (Glucagon-like Peptide 1 Receptor Agonist) on Overweight/Obese PCOS Patients
Ovarian Response to Recombinant Follicle Stimulating Hormone in Women With PCOS
Low Dose OC Therapy in Women With Polycystic Ovary Syndrome (PCOS): Impact of BMI on Hyperandrogenism
Effect of Nicotinic Acid on Cardiovascular Risks Indices in Polycystic Ovary Syndrome
Insulin Resistance, Polycystic Ovary Syndrome, and Bone Research Study
The Role of Dysbiosis of Gut Microbiota in the Pathogenesis of PCOS.
EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)
Saxagliptin + Metformin Compared to Saxagliptin or Metformin Monotherapy in PCOS Women With Impaired Glucose Homeostasis
Effect of Weight and Insulin Sensitivity on Reproductive Function in PCOS
Treatment of Infertility in Women With Polycystic Ovary Syndrome
A Study of Safety and Efficacy of Tildacerfont in Females With Polycystic Ovary Syndrome and Elevated Adrenal Androgens
Study of the Safety and Efficacy of Elagolix in Women With Polycystic Ovary Syndrome
Recombinant Versus Highly Purified FSH in Polycystic Ovary Syndrome (PCOS)
Lifestyle Intervention and Metformin for Women With Polycystic Ovary Syndrome (PCOS)
Single Ascending Dose, First-in-Human Study on Safety, Tolerability and Pharmacokinetics of BAY1161116
Targeting Pathways in Polycystic Ovary Syndrome (PCOS) Using Metformin (MET)
Suppression of Daytime and Nighttime Luteinizing Hormone Frequency by Progesterone
The Effect of Cinnamon Extract on Insulin Resistance Parameters in Polycystic Ovary Syndrome: A Pilot Study
The REBALANCE Study - a Prospective, Multicenter, Randomized, Pivotal Study of the May Health System
Feasibility Study of the AblaCare System in Transvaginal Ablation of Ovarian Tissue Under ULTRAsound Visualization in Women With Infertility Due to Polycystic Ovary Syndrome
A Trial of the May Health Device in Transvaginal Ablation of Ovarian Tissue Under ULTRAsound Visualization in Women With PCOS Infertility
Ovarian Hyperandrogenism in Normal and Excessive Body Weight Adolescent Girls and Their Relation to Diet (HAstudy)
OCP vs Metformin for Improvement in Clinical Symptoms and Metabolic Markers in Indian PCOS Women
A Study to Explore Correlation Between Symptoms and Signs of Polycystic Ovarian Syndrome (PCOS) and Risk of Over-response to Ovarian Stimulation
Urinary DENND1A.V2 as a Predictor of Pubertal Hyperandrogenemia
Effects of Inositol Alone or Associated With Alpha-lipoic Acid in Polycystic Ovary Syndrome Treatment
Metformin Treatment in Polycystic Ovary Syndrome (PCOS)
Clomiphene Citrate Plus uFSH Versus Aromatase Inhibitor Plus uFSH in Clomiphene Resistant Infertile PCOS Women
Go Girls! Fitness Support Group Intervention Effectiveness Study
Proteomics & Glyco-Proteomic Analysis of Follicular Fluid
Low Dose Growth Hormone in Obese PCOS Women
Clomiphene Citrate (CC) Co-treatment With HP Urinary FSH vs HP Urinary FSH in CC-resistant PCOS
Effect of Metformin on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone
Effects of Flutamide on Insulin and Glucose Metabolism in Women With Polycystic Ovary Syndrome
Pharmacogenetics of Metformin Action in PCOS
Metabolic Study of Women With Polycystic Ovary Syndrome and Sleep Apnea
Insulin and the Polycystic Ovary Syndrome--Weight Reduction Study
Cortisol Regulation in Polycystic Ovary Syndrome (PCOS)
Effects of Androgen Blockade on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone
Effect of Meal Composition on Postprandial Testosterone Concentration in Women With Polycystic Ovary Syndrome
The Genetics of Polycystic Ovarian Syndrome
Intrauterine Environment in Polycystic Ovary Syndrome (PCOS) Probands
Related Jobs in Women's Health
Urology Gynecology Sales Representative - Future Opportunity
Territory Representative - Birmingham
Medical Science Liaison, Women's Health
Medical Director, Women’s Health - MFM
General Medicines, Commercial Director, Menopause
Scientist, Reproductive & Molecular Biology
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.